• Contact us
Thursday, November 5, 2026
Register
Login
European Press
ADVERTISEMENT Handpicked deals on Amazon Discover useful products selected for our readers. Explore deals ›
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

Ozempic-like drugs linked to lower risk of developing diabetes in major study

5 November 2026
in Health
Reading Time: 3 mins read
A A
Ozempic-like drugs linked to lower risk of developing diabetes in major study
ShareShareShareShareShare


NEWYou can now listen to Fox News articles!
Adults with prediabetes and obesity who took GLP-1-based medications had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death compared with those taking metformin.Metformin is an oral medication used primarily to treat type 2 diabetes, widely considered the first-line treatment, combined with lifestyle modifications. It is also sometimes prescribed to people with prediabetes to help prevent or delay progression.The findings, which come from a large observational study, are set to be presented at the American Heart Association’s Scientific Sessions 2026 this weekend in Chicago. They have not yet undergone the full peer review process.DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN ‘JUMPSTART’ BETTER HEALTHThe study involved health records for 256,492 adults with prediabetes and obesity, averaging 52 years of age. Approximately half of the group received GLP-1 (glucagon-like peptide-1 receptor agonists) medications – including semaglutide, tirzepatide, liraglutide and dulaglutide – and half received metformin. Adults with prediabetes and obesity who took GLP-1-based medications had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death compared with those taking metformin. (iStock)Based on a three-year follow-up, in addition to the lower risk of diabetes and all-cause mortality, GLP-1–based medications were associated with 20% fewer strokes, 15% fewer heart attacks and 25% fewer cases of heart failure.”The 41% lower risk of death from any cause surprised me most,” study author Vinicius de Sousa Barzon Serra, M.D., a research fellow in the department of cardiovascular medicine at the Mayo Clinic in Scottsdale, Arizona, told Fox News Digital. Approximately half of the group received GLP-1 (glucagon-like peptide-1 receptor agonists) medications – including semaglutide, tirzepatide, liraglutide and dulaglutide – and half received metformin. (iStock)”I expected GLP-1 medications to do better than metformin on blood sugar and diabetes risk, because they lead to much more weight loss. I was also struck that the benefit appeared across many outcomes, including heart attack, stroke, heart failure and atrial fibrillation.”POPULAR DIET SLASHES LIVER FAT BY 67% WHILE REVERSING PREDIABETES IN SOME PEOPLENearly 40% of U.S. adults have prediabetes, according to statistics from the AHA. That condition is marked by blood sugar levels that are above normal but not yet elevated enough for a diabetes diagnosis.As many as 10% of those with prediabetes will go on to develop type 2 diabetes each year.CLICK HERE FOR MORE HEALTH STORIES”Most earlier research on these medications focused on people who already had diabetes,” Serra noted. “Our study suggests the prediabetes stage may be an important time to consider them, rather than waiting until they develop type 2 diabetes.” Nearly 40% of U.S. adults have prediabetes, according to statistics from the AHA. That condition is marked by blood sugar levels that are above normal but not yet elevated enough for a diabetes diagnosis. (iStock)The study did have some limitations. While it found a link between GLP-1 medications and better health outcomes, it does not prove that the drugs were responsible.CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTERThe findings are preliminary until published in a peer-reviewed journal, Serra noted.”We matched patients by age, health conditions and other characteristics to make the groups comparable … even so, other differences between the groups may remain,” he said. “We also grouped the GLP-1 medications together, so we could not tell whether individual drugs differ.” Metformin is an oral medication used primarily to treat type 2 diabetes, widely considered the first-line treatment, combined with lifestyle modifications. It is also sometimes prescribed to people with prediabetes to help prevent or delay progression. (Scott Olson/Getty Images)The study relied on patients’ electronic health records, which may have contained missing or incorrect information. It is also possible that factors not measured in the study, such as medication dosage and compliance, could have influenced the results, the researchers noted.TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZPeople with prediabetes and obesity should talk with their doctor about all their options and should not stop or change any medication on their own, Serra advised.CLICK HERE TO DOWNLOAD THE FOX NEWS APP”Metformin is a safe, inexpensive option with a long track record, and lifestyle changes such as healthy eating, regular physical activity and weight management remain the foundation of treatment,” he emphasized to Fox News Digital.”For some patients, a GLP-1 medication may be worth discussing, depending on their overall health, other medical conditions, cost and access. The decision should be made together with their doctor.” Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.

Credit: Source link

Previous Post

What Is an Energy Performance Certificate and Why Does It Matter?

Next Post

Frontier passenger claims airline took their seat, denied refund

Recommended

Rama: Italy-Albania migrant deal to last ‘for as long as need be’

Rama: Italy-Albania migrant deal to last ‘for as long as need be’

5 November 2026

Adrian Martinez signs with Seahawks after Sam Darnold injury reveal

Adrian Martinez signs with Seahawks after Sam Darnold injury reveal

5 November 2026

Adrian Martinez is back in the NFL as the former Jets quarterback heads to the Pacific Northwest to join the...

TikTok launches standalone TikTok Shop app (in four markets)

TikTok launches standalone TikTok Shop app (in four markets)

5 November 2026

TikTok has spent years making it easier to buy the products that appear in makeup tutorials, cooking videos, and creator...

Frontier passenger claims airline took their seat, denied refund

Frontier passenger claims airline took their seat, denied refund

5 November 2026

Talk about a rough landing. A Frontier Airlines passenger claims a booking glitch cost them their pre-assigned seat, their flight...

Datenschutzinformationen

Disclaimer  Privacy Policy – EU  Imprint 

Join European Press

Contact us

What’s New Here!

  • Rama: Italy-Albania migrant deal to last ‘for as long as need be’
  • Adrian Martinez signs with Seahawks after Sam Darnold injury reveal
  • TikTok launches standalone TikTok Shop app (in four markets)
  • Frontier passenger claims airline took their seat, denied refund

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

© 2026 European Press. All rights reserved.

European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video

© 2026 European Press. All rights reserved.

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?